

Australian Cystic Fibrosis Data Registry ACFDR

2021 Annual Report

The ACFDR collects information across 23 health services and uses this information to give doctors feedback to improve health outcomes.

3,616

People with CF



56%



44%

92 Newly Diagnosed

People in the Registry




76



16

Variants

MOST common variant
F508del



- Homozygous F508del (47%)
- Heterozygous F508del (43%)
- Other (10%)

COVID-19 Vaccination




89%



89%

Predicted Survival age



Predicted survival age of ACFDR cohort born in 2010-2014


Predicted survival age of ACFDR cohort born in 2016-2020

IV Antibiotics

Median number of days receiving IV AB in hospital



14



13

Clinical Encounters

% people with 4+ visits



76%




70%



63%

Telehealth

Percentage of visits



CF Related Diabetes

12 - 17



14%

18-29



24%

30+



30%

CFTR Modulators

55%



% of ELIGIBLE people who have been prescribed a CFTR modulator

Lung Function



median **FEV1 %** predicted